Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC for Refractory Crohn's Disease Lesions
NCT03901235Phase 2Recruiting
- Sponsor
- University of Liège
- Start
- Jan 2018
- Primary completion
- Dec 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Provacel in Crohn's disease, sponsored by University of Liège. Primary endpoints: Proportion of patients with deep ulcer healing at 12 weeks, Proportion of patients with stricture healing at 12 weeks and 2 more. Started Jan 2018; status: recruiting.
02
Drugs
Provacel
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03901235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901235.